Bortezomib-High Dose Melphalan Conditioning for the Treatment of MM Patients Undergoing ASCT

被引：0
|
作者：
Jimenez-Zepeda, Victor [1 ]
Duggan, Peter [1 ]
Neri, Paola [2 ]
Chaudhry, Ahsan [3 ]
Tay, Jason [4 ]
Luider, Joanne [5 ]
Bahlis, Nizar J. [2 ,6 ]
机构：
[1] Tom Baker Canc Clin, Dept Med Oncol & Hematol, Calgary, AB, Canada
[2] Univ Calgary, Arnie Charbonneau Canc Inst, Calgary, AB, Canada
[3] Tom Baker Canc Clin, Calgary, AB, Canada
[4] Univ Calgary Tom Baker Canc Ctr, Calgary, AB, Canada
[5] Alberta Hlth Services, Calgary, AB, Canada
[6] Univ Calgary, Calgary, AB, Canada
来源：
BLOOD | 2016年 / 128卷 / 22期
关键词：
D O I：
10.1182/blood.V128.22.2273.2273
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2273
引用
收藏
页数：5
相关论文
共 50 条
  • [21] Addition of bortezomib (Velcade™) to high dose melphalan (Vel-Mel) as an effective conditioning regimen with autologous stem cell support in multiple myeloma (MM).
    Hollmig, K
    Stover, J
    Talamo, G
    Zangari, M
    Thertulien, R
    van Rhee, F
    Fassas, A
    Anaissie, E
    Tricot, G
    Barlogie, B
    BLOOD, 2004, 104 (11) : 266A - 266A
  • [22] PK-Directed Intravenous Busulfan In Combination With High-Dose Melphalan and Bortezomib As Conditioning Regimen For Patients With Multiple Myeloma
    Barta, Stefan K.
    Mazumder, Amitabha
    Carter, Jason
    Almanzar, Lawrence
    Elkind, Richard
    Battini, Ramakrishna
    Derman, Olga
    Kornblum, Noah
    Xue, Xiaonan
    Verma, Amit
    Braunschweig, Ira
    BLOOD, 2013, 122 (21)
  • [23] PK-Directed Intravenous Busulfan in Combination with High-Dose Melphalan and Bortezomib As Conditioning Regimen for Patients with Multiple Myeloma
    Barta, Stefan Klaus
    Mazumder, Amitabha
    Carter, Jason
    Almanzar, Lawrence
    Elkind, Richard
    Battini, Ramakrishna
    Derman, Olga
    Kornblum, Noah
    Xue, Xionan
    Verma, Amit
    Braunschweig, Ira
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2014, 20 (02) : S104 - S105
  • [24] BORTEZOMIB IN COMBINATION WITH HIGH DOSE MELPHALAN AS CONDITIONING REGIMEN IS SAFE AND IMPROVES THE RESPONSE RATES IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
    Dalla Palma, B.
    Prezioso, L.
    Accardi, F.
    Manfra, I.
    Aversa, F.
    Giuliani, N.
    HAEMATOLOGICA, 2016, 101 : 789 - 790
  • [25] Bortezomib and high-dose melphalan conditioning for stem cell transplantation for AL amyloidosis: a pilot study
    Sanchorawala, Vaishali
    Quillen, Karen
    Sloan, J. Mark
    Andrea, Nancy T.
    Seldin, David C.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2011, 96 (12): : 1890 - 1892
  • [26] Busulfan, Melphalan, and Bortezomib versus High-Dose Melphalan as a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma
    Rodriguez, Tulio E.
    Hari, Parameswaran
    Stiff, Patrick J.
    Smith, Scott E.
    Sterrenberg, Danielle
    Vesole, David H.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2016, 22 (08) : 1391 - 1396
  • [27] Bortezomib and Melphalan (Bor/MEL) Conditioning for Patients with Multiple Myeloma Undergoing Single Autologous Stem Cell Transplantation
    Zepeda, Victor H. Jimenez
    Duggan, Peter
    Neri, Paola E.
    Bahlis, Nizar J.
    BLOOD, 2014, 124 (21)
  • [28] Impact of oral mucositis on outcomes of multiple myeloma patients treated with high-dose melphalan conditioning and autologous stem cell transplantation (ASCT).
    Jaguar, Graziella Chagas
    Rodrigues, Gustavo Henrique
    Guollo, Andre
    Camandoni, Vanessa Oliveira
    Magalhaes, Leila Maria
    Melo, Pessoa
    Alves, Fabio Abreu
    Cordeiro Lima, Vladmir Claudio
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [29] Bortezomib, Dexamethasone, and High-Dose Melphalan as Conditioning for Stem Cell Transplantation in Young Japanese Multiple Myeloma Patients: A Pilot Study
    Takezako, Naoki
    Sekiguchi, Naohiro
    Nagata, Akihisa
    Homma, Chiho
    Noto, Satoshi
    Miwa, Akiyoshi
    INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION, 2013, 29 (03) : 147 - 151
  • [30] Combining bortezomib to high dose melphalan as conditioning regimen results in the improvement of the response rate in newly diagnosed young multiple myeloma patients
    Dalla Palma, Benedetta
    Accardi, Fabrizio
    Prezioso, Lucia
    Notarfranchi, Laura
    Giuliani, Nicola
    LEUKEMIA & LYMPHOMA, 2020, 61 (05) : 1238 - 1241
12345